Sex, age at presentation affect cirrhosis response to therapy

March 30, 2013
Sex, age at presentation affect cirrhosis response to therapy
Among patients with primary biliary cirrhosis, sex and age at presentation affect the response to ursodeoxycholic acid, according to a study published in the March issue of Gastroenterology.

(HealthDay)—Among patients with primary biliary cirrhosis (PBC), sex and age at presentation affect the response to ursodeoxycholic acid (UDCA), according to a study published in the March issue of Gastroenterology.

Marco Carbone, from University of Cambridge in the United Kingdom, and colleagues analyzed data from 2,353 patients participating in the -PBC study. Data included diagnosis reports, response to therapy with UDCA, laboratory results, and symptom impact (assessed using the PBC-40 and other related measures).

The researchers found that 79 percent of the patients reported current UDCA therapy, with 80 percent of them meeting Paris response criteria. UDCA response was significantly lower in men than women (72 versus 80 percent). Male sex remained an of non-response on multivariate analysis. UDCA response was also strongly and independently associated with age at diagnosis, with response rates ranging from 90 percent among patients who presented with PBC when they were older than age 70 to less than 50 percent for those younger than age 30. Younger patients at presentation also were significantly more likely not to respond to UDCA therapy, based on alanine aminotransferase and aspartate response criteria, but were more likely to report and pruritus. Women had significantly higher mean fatigue scores than men (32 percent higher) that were related strongly to higher levels of autonomic symptoms.

"Among patients with PBC, response to UDCA, treatment, and symptoms are related to sex and age at presentation, with the lowest rates and highest levels of symptoms in women presenting at younger than age 50," the authors write.

Explore further: New research may lead to earlier diagnosis and treatment of primary biliary cirrhosis in families

More information: Abstract
Full Text

Related Stories

Recommended for you

New drug to fight fatal but neglected tropical disease

August 31, 2016

In a breakthrough for those infected by the parasites that cause sleeping sickness, a young Queensland researcher has identified a compound that kills the parasites in the lab without having any toxic effect on human cells.

Traces of Ebola virus linger longer than expected in semen

August 31, 2016

Initial data from a Liberian public health program show about 9 percent (38) of 429 male Ebola survivors had fragments of Ebola virus in their semen. Of those, 63 percent had semen samples that tested positive for Ebola fragments ...

Researchers discover a drug for a tropical disease

August 30, 2016

Researchers at the University of Georgia are working to find the fastest way possible to treat and cure human African trypanosomiasis, long referred to as sleeping sickness. By working to improve chemical entities already ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.